Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial-Reference-Cited by-同舟云学术

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

Published:2022-09 Issue:9 Volume:9 Page:e648-e659
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

de Latour Régis Peffault,Szer Jeff,Weitz Ilene C,Röth Alexander,Höchsmann Britta,Panse Jens,Usuki Kensuke,Griffin Morag,Kiladjian Jean-Jacques^ORCID,de Castro Carlos M,Nishimori Hisakazu,Ajayi Temitayo,Al-Adhami Mohammed,Deschatelets Pascal,Francois Cedric,Grossi Federico,Risitano Antonio M,Hillmen Peter

Funder

Apellis Pharmaceuticals

Publisher

Elsevier BV

Subject

Hematology

Reference34 articles.

1. Paroxysmal nocturnal haemoglobinuria;Hill;Nat Rev Dis Primers,2017

2. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene;Bessler;EMBO J,1994

3. Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria;Hillmen;Proc Natl Acad Sci USA,1993

4. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria;Boccuni;Crit Rev Oncol Hematol,2000

5. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the “b”domain of C9;Ninomiya;J Biol Chem,1992

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria;Expert Review of Clinical Pharmacology;2024-09-11

2. Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy;Oncohematology;2024-09-01

3. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

4. Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval;International Journal of Molecular Sciences;2024-08-09

5. Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function;International Journal of Molecular Sciences;2024-08-06